Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics

They're already competing in fresh markets now that their COVID test revenue is ebbing.

Got $1,500? These 2 COVID Stocks Are Firing On All Cylinders

SALT LAKE CITY, Oct. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2021 results on Thursday, November 11, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Third Quarter 2021 Earnings Release Date And Webcast

Co-Diagnostics Inc., revealed that CoSara Diagnostics Pvt Ltd., its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic (IVD).

Co-Diagnostics says its CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test

Co-Diagnostics says it CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test

SALT LAKE CITY, Oct. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic ("IVD"). The CDSCO approval marks the 10th assay manufactured and sold by CoSara to receive clearance from the CDSCO, and follows the recent clearance of standalone dengue and chikungunya assays last month.

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for Dengue/Chikungunya Multiplex Test

Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does:  Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.

Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform for the masses

Co-Diagnostics, Inc. has said it will be introducing its upcoming at-home and point-of-care PCR device at a press conference at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo being held September 26-30, 20321, in Atlanta, Georgia.

Co-Diagnostics to introduce its upcoming at-home and point-of-care PCR device at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo

SALT LAKE CITY, Sept. 27, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be introducing its upcoming at-home and point-of-care PCR device in a press conference at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, held September 26-30 in Atlanta, GA, as well as hosting a booth to promote its existing suite of diagnostics products and technology applications.

Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28

Co-Diagnostics Inc. is rebranding its image to better reflect its growing scope, mission, and upcoming expansion into new diagnostics verticals.

Co-Diagnostics announces corporate rebranding after period of transformative growth and expansion

SALT LAKE CITY, Sept. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following its recent transformative growth, the Company is rebranding its image to better reflect its expanded scope, mission, and upcoming expansion into new diagnostics verticals.

Co-Diagnostics, Inc. Announces Corporate Rebranding Following Period of Transformative Growth and Expansion

SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company representatives will be presenting at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, held on September 22-25, 2021.

Co-Diagnostics, Inc. to Present at ACTC Liquid Biopsy Conference in Kalamata, Greece

Co-Diagnostics Inc has announced that its Logix Smart Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology (InDRE) after the department successfully concluded an independent evaluation of the test's sensitivity and specificity for use as an RT-PCR multiplex test in that market. The InDRE, which is comparable to the US Centers for Disease Control and Prevention (CDC), is required to evaluate any test used to detect coronavirus (COVID-19) before the test may gain clearance to be sold into the Mexican healthcare market, Co-Diagnostics said.

Co-Diagnostics says its Logix Smart ABC Test is authorized for use in Mexico

SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology ("InDRE") after InDRE successfully concluded an independent evaluation of the test's sensitivity and specificity for use as an RT-PCR multiplex test in that market.

Co-Diagnostics, Inc. Logix Smart™ ABC Test Authorized for Use in Mexico

SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Fall Virtual Investor Conference.

Co-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference

Co-Diagnostics (NASDAQ:CODX) Inc has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene dengue and chikungunya RT-PCR tests as in vitro diagnostics (IVD). The Saragene test kits approved by the CDSCO use the company's patented CoPrimer technology for the qualitative detection of these mosquito-borne viruses.

Co-Diagnostics says its CoSara JV received regulatory clearance in India for Saragene dengue and chikungunya tests

Co-Diagnostics Inc has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene dengue and chikungunya RT-PCR tests as in vitro diagnostics (IVD). The Saragene test kits approved by the CDSCO use the company's patented CoPrimer technology for the qualitative detection of these mosquito-borne viruses.

Co-Diagnostics says its CoSara JV received regulatory clearance in India for Saragene dengue and chikunguny tests

SALT LAKE CITY, Sept. 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics ("IVD").

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

SALT LAKE CITY, Sept. 13, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion hosted by Scott Gottlieb, M.D.

Co-Diagnostics, Inc. CEO to Participate in Panel Discussion with Scott Gottlieb, M.D., at H.C. Wainwright 2021 Annual Global Investor Conference

Co-Diagnostics Inc. reports that its Logix Smart COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus.

Co-Diagnostics says its Logix Smart COVID-19 Test Kit used to confirm presence of coronavirus including mutated strains in Italy

SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus, in a community surveillance method of testing single-use waste, with the peer-reviewed results published in the journal Science of the Total Environment.

Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy

SALT LAKE CITY, Aug. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting and hosting a booth this week at the 13th Annual Next Generation Dx Summit on Aug 24-26 in Washington, D.C. The Next Generation Dx Summit, offering complete coverage of timely and important issues for the diagnostics industry, is comprised of the Enabling Point-of-Care Diagnostics testing (POCT) stream, and the Companion Diagnostics and Liquid Biopsy stream.

Co-Diagnostics, Inc. To Present At 13th Next Generation Dx Summit In Washington, D.C.

Co-Diagnostics shares rallied after the company posted strong quarterly results. Total addressable market expanding.

Why Co-Diagnostics Is A Solid Covid-19 Play

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

CoDiagnostics, Inc. (CODX) Just Reclaimed the 20-Day Moving Average

The company notched beats on both trailing and anticipated revenue and earnings.

Why Co-Diagnostics Zoomed Almost 10% Higher Today

Co-Diagnostics Inc's (NASDAQ: CODX) Q2 revenue increased 14% Y/Y to $27.4 million, primarily due to Logix Smart COVID-19 Test sales, beating the consensus of $20.77 million. Gross profit increased 37.6% to $24.9 million, with margin expanding to 90.8% from 75.1% in Q2 FY20 due to reduced production costs and improved product mix compared to the prior-year period.

News for Co-Diagnostics Stock (CODX)